9 results on '"Marianne Berg"'
Search Results
2. Examining the psychometric properties of the Norwegian version of the Social Aptitudes Scale in two clinical samples
- Author
-
Kaiser, Sabine, primary, Mathiassen, Børge, additional, Handegård, Bjørn Helge, additional, Arnesen, Yngvild, additional, and Halvorsen, Marianne Berg, additional
- Published
- 2023
- Full Text
- View/download PDF
3. General Measurement Tools for Assessing Mental Health Problems Among Children and Adolescents with an Intellectual Disability: A Systematic Review
- Author
-
Halvorsen, Marianne Berg, primary, Helverschou, Sissel Berge, additional, Axelsdottir, Brynhildur, additional, Brøndbo, Per Håkan, additional, and Martinussen, Monica, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
- Author
-
Maren Høland, Anita Sveen, Sharmini Alagaratnam, Arild Nesbakken, Kaja Christine Graue Berg, Ragnhild A. Lothe, Stine A. Danielsen, Marianne Berg, and Kjetil Søreide
- Subjects
Male ,0301 basic medicine ,Cancer Research ,DNA Copy Number Variations ,DNA Mutational Analysis ,Gene Dosage ,Biology ,medicine.disease_cause ,Article ,03 medical and health sciences ,0302 clinical medicine ,Chromosome instability ,Gene expression ,Cancer genomics ,Tumor Microenvironment ,Genetics ,medicine ,Humans ,Molecular Biology ,Gene ,Regulation of gene expression ,Gene Expression Profiling ,Gene Amplification ,Microsatellite instability ,medicine.disease ,Colorectal cancer ,Survival Analysis ,Gene Expression Regulation, Neoplastic ,Gene expression profiling ,030104 developmental biology ,Molecular Diagnostic Techniques ,TOX3 ,030220 oncology & carcinogenesis ,Cancer research ,Female ,Microsatellite Instability ,Colorectal Neoplasms ,Transcriptome ,Carcinogenesis ,Microsatellite Repeats - Abstract
About 80% of colorectal cancers (CRCs) have chromosomal instability, which is an integral part of aggressive malignancy development, but the importance of specific copy number aberrations (CNAs) in modulating gene expression, particularly within the framework of clinically relevant molecular subtypes, remains mostly elusive. We performed DNA copy number profiling of 257 stage I-IV primary CRCs and integrative gene expression analysis in 151 microsatellite stable (MSS) tumors, focusing on high-level amplifications and the effect of CNAs on the characteristics of the gene expression-based consensus molecular subtypes (CMS). The results were validated in 323 MSS tumors from TCGA. Novel recurrent high-level amplifications (≥15 additional copies) with a major impact on gene expression were found for TOX3 (16q) at 1.5% frequency, as well as for CCND2 (12p) and ANXA11 (10q) at 1% frequency, in addition to the well-known targets ERBB2 (17q) and MYC (8q). Focal amplifications with ≥15 or ≥5 additional copies of at least one of these regions were associated with a poor overall survival among patients with stage I-III MSS CRCs (multivariable hazard ratio ≥3.2, p ≤ 0.01). All high-level amplifications were focal and had a more consistent relationship with gene expression than lower amplitude and/or broad-range amplifications, suggesting specific targeting during carcinogenesis. Genome-wide, copy number driven gene expression was enriched for pathways characteristic of the CMS2-epithelial/canonical subtype, including DNA repair and cell cycle progression. Furthermore, 50% of upregulated genes in CMS2-epithelial/canonical MSS CRCs were driven by CNAs, an enrichment compared with the other CMS groups, and associated with the stronger correspondence between CNAs and gene expression in malignant epithelial cells than in the cells of the tumor microenvironment (fibroblasts, endothelial cells, leukocytes). In conclusion, we identify novel recurrent amplifications with impact on gene expression in CRC and provide the first evidence that CMS2 may have a stronger copy-number related genetic basis than subtypes more heavily influenced by gene expression signals from the tumor microenvironment. publishedVersion
- Published
- 2019
5. Determinants of caregiver satisfaction with child neurodevelopmental assessment in neuropaediatric clinics
- Author
-
Marianne Berg Halvorsen, Katarina Smejda Kjaerandsen, and Per Håkan Brøndbo
- Subjects
Caregiver experiences ,Caregiver satisfaction ,medicine.medical_specialty ,Adolescent ,Referral ,VDP::Social science: 200::Psychology: 260 ,Personal Satisfaction ,Neurodevelopmental assessment ,Norwegian ,Health informatics ,Health administration ,03 medical and health sciences ,0302 clinical medicine ,Neuropaediatric ,Surveys and Questionnaires ,Humans ,Medicine ,Family ,030212 general & internal medicine ,Child ,Socioeconomic status ,Norway ,business.industry ,lcsh:Public aspects of medicine ,030503 health policy & services ,Health Policy ,Nursing research ,Public health ,Health care surveys ,lcsh:RA1-1270 ,language.human_language ,Caregivers ,Health care services research ,Child, Preschool ,Family medicine ,VDP::Samfunnsvitenskap: 200::Psykologi: 260 ,Respondent ,language ,Female ,0305 other medical science ,business ,Research Article - Abstract
BackgroundIn addition to patient evaluations, caregiver evaluations and experiences are important indicators of the quality of health services. The aim of this study was to examine determinants of caregiver satisfaction with and perceived benefit of child neurodevelopmental assessment in neuropaediatric clinics.MethodsThe study was conducted among caregivers of children and adolescents aged 4–18 years (N = 330) referred for neurodevelopmental assessment in two neuropaediatric clinics in the specialised health service in Northern Norway. The Generic Short Patient Experiences Questionnaire (GS-PEQ) for child psychiatric outpatient patients was distributed to caregivers immediately following the assessment, and two of its items were used as measurements of caregiver satisfaction with and perceived benefit of the assessment.ResultsCaregiver satisfaction with the assessment was correlated with a better general level of function in the child, higher socioeconomic status, Norwegian mother tongue, referral from a specialist, and the respondent being a woman. Higher perceived benefit of the assessment was correlated with higher socioeconomic status, Norwegian mother tongue, and younger age of the child. Regression analysis revealed that caregivers’ perception that the assessment was suited to their child’s situation and that there was good cooperation with other public services (e.g., primary care and social/educational services) seemed more fundamental to caregiver satisfaction with neuropaediatric clinics’ services than any background variable. Younger age of the child, in addition to caregivers’ perception that the assessment was suited to their child and receiving sufficient information about the child’s diagnosis/afflictions, were essential to the perceived benefit of the assessment.ConclusionsCaregiver satisfaction with child neurodevelopmental assessment in neuropaediatric clinics partly depends on variables not related to the assessment experience per se. An assessment that was suited to the child, good cooperation with other public services such as primary health care and social/educational services, and giving sufficient information about the child’s diagnosis are essential to an overall positive caregiver evaluation of neurodevelopmental assessments.
- Published
- 2021
6. Determinants of caregiver satisfaction with child neurodevelopmental assessment in neuropaediatric clinics
- Author
-
Kjærandsen, Katarina Smejda, primary, Brøndbo, Per Håkan, additional, and Halvorsen, Marianne Berg, additional
- Published
- 2021
- Full Text
- View/download PDF
7. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
- Author
-
Ola Myklebost, Ragnhild A. Lothe, Paul Noordhuis, Marianne Berg, Erik B. Paulsen, Lyubomir T. Vassilev, and Hege O. Ohnstad
- Subjects
Cancer Research ,medicine.medical_treatment ,Antineoplastic Agents ,Pharmacology ,lcsh:RC254-282 ,Piperazines ,Cell Line, Tumor ,Genetics ,medicine ,Humans ,Cytotoxic T cell ,Doxorubicin ,neoplasms ,Cell Proliferation ,Chemotherapy ,biology ,Cytotoxins ,business.industry ,Imidazoles ,Antagonist ,Drug Synergism ,Proto-Oncogene Proteins c-mdm2 ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Oncology ,Apoptosis ,Cancer research ,biology.protein ,Mdm2 ,Sarcoma ,Tumor Suppressor Protein p53 ,Signal transduction ,business ,Signal Transduction ,Research Article ,medicine.drug - Abstract
Background Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic approaches. The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently induces apoptosis in tumours with amplified MDM2 gene and overexpression of MDM2 protein. However, the majority of human sarcomas have normal level of MDM2 and the therapeutic potential of MDM2 antagonists in this group is still unclear. We have investigated if Nutlin-3a could be employed to augment the response to traditional therapy and/or reduce the genotoxic burden of chemotherapy. Methods A panel of sarcoma cell lines with different TP53 and MDM2 status were treated with Nutlin-3a combined with Doxorubicin, Methotrexate or Cisplatin, and their combination index determined. Results Clear synergism was observed when Doxorubicin and Nutlin-3a were combined in cell lines with wild-type TP53 and amplified MDM2, or with Methotrexate in both MDM2 normal and amplified sarcoma cell lines, allowing for up to tenfold reduction of cytotoxic drug dose. Interestingly, Nutlin-3a seemed to potentiate the effect of classical drugs as Doxorubicin and Cisplatin in cell lines with mutated TP53, but inhibited the effect of Methotrexate. Conclusion The use of Nutlin in combination with classical sarcoma chemotherapy shows promising preclinical potential, but since clear biomarkers are still lacking, clinical trials should be followed up with detailed tumour profiling.
- Published
- 2011
8. Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas
- Author
-
Franclim R. Ribeiro, Carmen Jerónimo, Rui Henrique, Manuel R. Teixeira, Ragnhild A. Lothe, Marianne Berg, and Merete Hektoen
- Subjects
Male ,Cancer Research ,Gene Dosage ,Locus (genetics) ,lcsh:RC254-282 ,Gene dosage ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,medicine ,Humans ,PTEN ,In Situ Hybridization, Fluorescence ,030304 developmental biology ,Chromosome Aberrations ,Genetics ,0303 health sciences ,biology ,medicine.diagnostic_test ,Genome, Human ,Research ,Breakpoint ,Nucleic Acid Hybridization ,Prostatic Neoplasms ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,Mutation ,biology.protein ,Molecular Medicine ,Tumor Suppressor Protein p53 ,Virtual karyotype ,Comparative genomic hybridization ,Fluorescence in situ hybridization - Abstract
Background In order to gain new insights into the molecular mechanisms involved in prostate cancer, we performed array-based comparative genomic hybridization (aCGH) on a series of 46 primary prostate carcinomas using a 1 Mbp whole-genome coverage platform. As chromosomal comparative genomic hybridization (cCGH) data was available for these samples, we compared the sensitivity and overall concordance of the two methodologies, and used the combined information to infer the best of three different aCGH scoring approaches. Results Our data demonstrate that the reliability of aCGH in the analysis of primary prostate carcinomas depends to some extent on the scoring approach used, with the breakpoint estimation method being the most sensitive and reliable. The pattern of copy number changes detected by aCGH was concordant with that of cCGH, but the higher resolution technique detected 2.7 times more aberrations and 15.2% more carcinomas with genomic imbalances. We additionally show that several aberrations were consistently overlooked using cCGH, such as small deletions at 5q, 6q, 12p, and 17p. The latter were validated by fluorescence in situ hybridization targeting TP53, although only one carcinoma harbored a point mutation in this gene. Strikingly, homozygous deletions at 10q23.31, encompassing the PTEN locus, were seen in 58% of the cases with 10q loss. Conclusion We conclude that aCGH can significantly improve the detection of genomic aberrations in cancer cells as compared to previously established whole-genome methodologies, although contamination with normal cells may influence the sensitivity and specificity of some scoring approaches. Our work delineated recurrent copy number changes and revealed novel amplified loci and frequent homozygous deletions in primary prostate carcinomas, which may guide future work aimed at identifying the relevant target genes. In particular, biallelic loss seems to be a frequent mechanism of inactivation of the PTEN gene in prostate carcinogenesis.
- Published
- 2006
9. Will an aspirin a day keep the colorectal cancer away?
- Author
-
Marianne Berg and Kjetil Søreide
- Subjects
Oncology ,medicine.medical_specialty ,Aspirin ,Cancer prevention ,business.industry ,Colorectal cancer ,Incidence (epidemiology) ,medicine.disease ,Healthy individuals ,Internal medicine ,medicine ,business ,medicine.drug - Abstract
A long-term follow-up study that assessed the effect of daily aspirin on colorectal cancer incidence concluded that it significantly reduced the risk of colon cancer, but not rectal cancer. Detailed analysis of the findings indicate that it is too soon to recommend daily aspirin for cancer prevention in healthy individuals.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.